Armatus Bio
- Biotech or pharma, therapeutic R&D
Armatus Bio is a privately held, late preclinical-stage company utilizing vectorized RNAi in autosomal dominant neuromuscular diseases, with technology licensed from Nationwide Children’s Hospital in Columbus, Ohio. The company is advancing candidates for CMT1A and FSHD, both relatively common orphan indications with 70,000 and 30,000 affected patients in the US, respectively, and with no FDA-approved medicines. Both of Armatus’ lead assets have completed preINDs and have been assigned ODD and RPD; the company is now preparing for IND-enabling studies, with the goal of delivering its first IND in 2026. Armatus is seeking Series A funding to advance the pipeline toward clinical proof of concept and is open to a range of partnering opportunities.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}